161 results on '"de Castro, J."'
Search Results
2. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
3. Deceased donor kidney procurement: Systematic review of the surgical technique
4. Macrophage cell membrane infused biomimetic liposomes for glioblastoma targeted therapy
5. Revision of TD1 and TD2 stratigraphic sequence of Gran Dolina cave (Sierra de Atapuerca, Spain)
6. Laparoscopic nephron sparing surgery and radical nephrectomy in cT1 renal tumors. Comparative analysis of complications and survival
7. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis
8. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer
9. CARACTERIZAÇÃO FÍSICO-QUÍMICA DE ABACAXI CULTIVAR PÉROLA, COMERCIALIZADOS NO MUNICÍPIO DE SANTARÉM – PARÁ
10. Nanotechnology boosts the production of clean energy via nanoparticle addition in anaerobic digestion
11. Cumulative Distribution Functions as Hysteresis Models.
12. Variation of quality of life in patients with obstructive sleep apnea hipopnea syndrome after treatment with mandibular advance device
13. Effects of Resistance Training with Blood Flow Restriction on Muscle Strength and Biomarkers in Older People: A Systematic Review of Randomized Clinical Trials
14. P2.14-01 Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC
15. P2.14-04 Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study
16. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy
17. Risk of detecting prostate cancer based on the PSAD and PIRADS lesions in MRI in patients with a negative previous biopsy.
18. Quality of life in patients with Non-Muscle Invasive Bladder Cancer (NMIBC) subjected to intravesical instillations with BCG induction
19. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
20. Mer for cognition: an emotion analysis algorithm in identifying moods of song and valence through musical features
21. Ovidian verses in El licenciado Vidriera
22. Prognostic Potential of Candidate miRNAs in Lung Cancer: Insights from Tissue and Liquid Biopsies
23. Glioma Patient Management: Utilizing MGMT Methylation in Extracellular Vesicle-Based Liquid Biopsy
24. PP01.17 Sotorasib in Advanced KRAS p.G12C–Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP)
25. Evaluation of Endo 10 mobile application as diagnostic tool in endodontics
26. EP.13A.05 Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
27. P1.13A.11 Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study.
28. EE495 Cost-Effectiveness Analysis of Adjuvant Atezolizumab Versus Best Supportive Care in the Treatment of Patients With Resectable Early-Stage Non-Small Cell Lung Cancer and PD-L1≥50% Expression
29. Prostate rebiopsy in patients with a negative previous biopsy and MRI. When should it be done?
30. Basal characteristics of the prospective spanish immunotherapy registry of cardiovascular toxicity: SIR-CVT
31. P3.08E.04 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials
32. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study
33. EP08.02-131 Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program
34. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial
35. 989P Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)
36. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
37. EP08.01-049 Unscheduled Hospitalizations in Patients With Thoracic Tumors in the Era of Immunotherapy
38. Nefrectomía parcial y radical laparoscópica en tumores renales cT1. Análisis comparativo de complicaciones y supervivencia
39. Revision of TD1 and TD2 stratigraphic sequence of Gran Dolina cave (Sierra de Atapuerca, Spain)
40. 32P Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis
41. Immunogenic evaluation of collagen and gelatin from marine origin envisioning tissue engineering-related applications
42. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
43. Study of the immunologic response of marine-derived collagen and gelatin extracts for tissue engineering applications
44. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
45. P267 - Quality of life in patients with Non-Muscle Invasive Bladder Cancer (NMIBC) subjected to intravesical instillations with BCG induction
46. P037 - Risk of detecting prostate cancer based on the PSAD and PIRADS lesions in MRI in patients with a negative previous biopsy.
47. 16MO Clinical impact of plasma EGFR analysis: Results from the ETOP-BOOSTER randomized phase II trial
48. P032 - Prostate rebiopsy in patients with a negative previous biopsy and MRI. When should it be done?
49. EP15.03-04 Unscheduled Hospitalizations in Patients with Lung Cancer as a Frailty Event.
50. MA16.04 Circulating Tumor DNA Quantification by NGS Should Be Adapted to the Methodology Used.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.